En

ABOUT HOOMYA

關于宏雅



深圳市賽百諾中加基因技術有限公司♠↕♣&是(shì)由臨床藥理(lǐ)學家(jiā)、我國(guó)"£遺傳藥理(lǐ)學與藥物(wù)基因組學"≈‌的(de)開(kāi)拓者和(hé)奠基人(rén)、個(​♠‌®gè)體(tǐ)化(huà)醫(yī)學的(de)倡導者和(hé)‌>©引領者周宏灏院士及其團隊發起設立，緻力于個(gè)體(tǐ)化(hu"¥§à)醫(yī)學（精準醫(yī)學）檢測技(jì)術(s₽≤→hù)的(de)研究與産業(yè)化(huà)的(de)高(gāo)科(↔↕kē)技(jì)公司。公司主要(yào)從(cóng)事(shì)λβ&♣個(gè)體(tǐ)化(huà)醫(yī)學檢測産品（含産品≥♦±科(kē)研、CDMO、儀器(qì)與設備、試劑耗材及檢測服務）的(de)開(↕∏₹®kāi)發、運營與市(shì)場(chǎng)推廣，打造精準醫(✔‌>yī)學時(shí)代的(de)專業(y ←™↑è)個(gè)體(tǐ)化(huà)醫(yī)學檢測運營服務平台.

Hunan Hongya Gene Technology Co.,↓∏  Ltd. was founded by academician✘✘‍ Zhou Honghao, a clin$♠"ical pharmacologist, pioneer and found↑↔er of pharmacogenetics and pharmacog≤ enomics in my country, and advoca₹→↕'te and leader of personalized σ✘₽medicine, and his team. It is a highε₹∞-tech company dedicat≠ ed to the research and ind$♦©ustrialization of personalized medicin>♣÷λe (precision medicine) testing techno₽♥logy. The company is mainly engaged&ασ₹ in the development, operation and ma↔✘rketing of personaliz™λ©←ed medicine testing products (inc‌Ω§luding product research, CDMO≤δ​, instruments and equipment, £©∑reagents and consumables, and tesπ←↔"ting services), creating a prφ≠‍ofessional personalized medicine&  testing operation service platfo✔Ωrm in the era of preci✔∞sion medicine.





公司聯合以湘雅醫(yī)學檢驗所為(wè≠♣∞i)主體(tǐ)的(de)國(guó)內(nèi)外(wài)多(duō)家★∑€(jiā)個(gè)體(tǐ)化(huà)醫(yī)學（$ ₽≥精準醫(yī)學)專業(yè)研究機(jī)構，÷₹ΩΩ引進頂尖學者、 美(měi)國(gu≈∏ ó)墨菲特癌症中心醫(yī)學主任霍華德 · L · 麥克勞德為(wèi)代表的(de)專家(jiā)技(jì)術(shù)團隊，整合國(gπ₩♦uó)內(nèi)外(wài)先進的(de)個(gè∏≈)體(tǐ)化(huà)醫(yī)學檢測技("£"εjì)術(shù)平台， 以研發帶動生(shē£"×ng)産和(hé)銷售，依托具有(yǒu)先進性的( ₽•♣de)分(fēn)子(zǐ)診斷核心技(jì)術(shù♣÷)，在體(tǐ)外(wài)診斷，尤其是(shì)高(gāo)端的(de)分(φ₽∏♣fēn)子(zǐ)診斷領域形成了(le) 一(y€✔ī)系列具有(yǒu)自(zì)主知(zhī)識α✘≥$産權的(de)産品。
    The company has ☆♥ joined forces with a nu•'mber of Personalized me <✔dicine (precision me>™ dicine) professional res÷π♥ earch institutes at  £home and abroad, mainly✔✔ based on the Xiangya medical↑>≠ laboratory, howard L. McCloud, medα ≤ical director of the Murphy Cancer C©‌enter in the United ¥↔States and a leading scholar, was b©∞rought in to represent the♠ε ♥ expert and technical team to integra✔σ≈£te advanced Personalized medici₩∏ne detection technology platforα≤αms at home and abroad, a series of prodδ®ucts with independent intellectual'< property rights have been dev∏ε☆eloped in the field of in ©β∑∞vitro diagnosis, especially in high-↑♥βend molecular diagnosis.

公司目前主營業(yè)務包括各類應用(yòng)于無創産前篩查δδ™₹、疾病預測、疾病早期篩查、疾病早期分(fēn)子(zǐ)診斷與分φ£α(fēn) 子(zǐ)分(fēn)÷ππ型、疾病個(gè)體(tǐ)化(huà)用(yòng)藥指導、疾病預後​☆∏監測的(de)分(fēn)子(zǐ)檢測産品，已形成覆蓋全國(g≠≈φπuó)的(de)營銷網絡，成為(wèi)個(g​€<>è)體(tǐ)化(huà) 醫(yī)學（₩€​₽精準醫(yī)學）專業(yè)服務領域的(de) ©♥ 優勢品牌企業(yè)。
   &nbδ<sp;At present, the company's mainβλ business includes vari✔‍ous applications in non-i∑×nvasive prenatal screening, disease p<↔§rediction, disease early ₩≠≈screening, disease early molecular dia♣£gnosis and classification, the ​←λαmolecular detection product←>$​s of sub-typing, disease≥>&™ individualized medication guida¥≤♠nce and disease prognosis moniε↑£∞toring have formed a na↔σλtionwide marketing network and<↔≈Ω become individualiz♥♦ed, medical (precision medi"∏✔±cine) professional services i₽±<>n the field of dominant brand enterprisΩ&'>es

技(jì)術(shù)團隊Technical Team

公司聯合以湘雅醫(yī)學檢驗所為(wèi)主體(tǐ)×¥∑的(de)國(guó)內(nèi)外(w→λ≠ài)多(duō)家(jiā)個(gè)體(t♣•Ωǐ)化(huà)醫(yī)學（精準醫(yī)學）專業(yè)研究機≈®(jī)構，引進以 頂尖學者、美(měi)國(guó ₩δ)墨菲特癌症中心醫(yī)學主任霍華德 · L · 麥克勞德d為(wèi)代表的(de)專家(jiā)技(jì≠λ&")術(shù)團隊，整合 國(guó)內(nèβ÷i)外(wài)先進的(de)個(gè)體(tǐ)化(huà)醫‌₽(yī)學檢測技(jì)術(shù)平台，以研↑♠發帶動生(shēng)産和(hé)銷售，依托具有(yǒu)先進性的(de)>∞♦分(fēn)子(zǐ)診斷核心技(jì)術(shù)∞&， 在體(tǐ)外(wài)診斷，尤其是(shì)高(g₩<āo)端的(de)分(fēn)子(zǐ)診斷領域形成了(le)一(←β≤™yī)系列具有(yǒu)自(zì)主知(zhī)識産權的(de)産品。
The company has teamed up wit♦↔h a number of Personalized me'φ dicine (precision medicine) profes€←×sional research institutes at home an☆δd abroad, mainly based on the Xiangyε÷a medical laboratory®$±♠, howard L. McCloud D, medi↕↑"↓cal director of the Murphy Ca≈£©∏ncer Center and a leadin¥$g scholar, is the represeλ∑λΩntative of the expert and technic↕♣ &al team, which integr∑§ates the advanced Personalized medicine÷≤ detection technolog​♣♥™y platform at home and abroad,↔ ☆ in vitro diagnosis, especially γ≤in high-end molecular di✔¶≤agnosis field, has f♠®±÷ormed a series of products with inπ♠dependent intellectual property βσrights, relying on advanc←σ∏ed molecular diagnosis core techn®$×ology.

主營業(yè)務Business

公司目前主營業(yè)務包括各類應用(yòn$→©♥g)于無創産前篩查、疾病預測、疾病早期篩查、疾病早期分(fēn)子(zǐ)診‌♠¶斷與分(fēn)子(zǐ) 分(fēn)型、疾₽ δ病個(gè)體(tǐ)化(huà)用(yòng)藥指導、疾病預後監測σ✘‌的(de)分(fēn)子(zǐ)檢測産品，業(yè)務版↓α圖已遍布湖(hú)南(nán)、湖(hú)北(bě•✘₩i)、江蘇、浙 江、安徽、上(shàng)海σ∏(hǎi)、北(běi)京、天津、河(hé)南(nán≈€≥)、河(hé)北(běi)、山(shān)東$&±×(dōng)、山(shān)西(xī)、陝西(xī ™)、遼甯、廣東(dōng)、廣西(xī)、雲南(nánΩ β)、 貴州等地(dì)區(qū)。
At present, the company's main busine↔★σss includes various applicati←✘÷'ons in non-invasive prenatal scree<↓​₹ning, disease predict®♥±βion, disease early scree ‍"ning, disease early molecular ↑Ω®&diagnosis and molecular, molecσ±ular testing products for typing, &α®individualized medication guidance, and←§  disease prognosis monitoring ε, the business scope has sprea←×σd over Hunan, Hubei, Jiangsu,→ α Zhejiang, Anhui, Shaφ nghai, Beijing, Tianjin, Henan, ≈→±♣Hebei, Shandong, Shanxi, Sh©‍aanxi, Liaoning, Guangdongφπ"", Guangxi, Yunnan, Guizhou and ←Ω¥other regions.

行(xíng)業(yè)領域Industry sector

個(gè)體(tǐ)化(huà)醫(yī☆®×)學Personalized Medicine 

個(gè)體(tǐ)化(huà)§♦醫(yī)學是(shì)21世紀醫(yī)學發展Ω↔ ₽的(de)必然趨勢。随著(zhe)人(rén)類基因組計(€®"jì)劃的(de)完成和(hé)後基因組學的(de)深入研究， ∞™®→ 越來(lái)越多(duō)的(de)緻病基✔®≤±因被定位，更多(duō)疾病發生(shēng)的(de>​)遺傳學基礎得(de)以闡明(míng)，與人(rén)類生(↑$↑↕shēng)理(lǐ)、病理(lǐ)以及藥物(wù)效應 £γλ¥和(hé)毒副反應相(xiàng)關的(de)基因特征不(♥'♣¶bù)斷被揭示，促使醫(yī)學模式由經典的(de)基于規律總結的(∞$de)“标準化(huà)醫(yī)學”，向基 ≥¶ 于個(gè)體(tǐ)基因差異進行(α‍÷∏xíng)的(de)“量體(tǐ)裁衣”式的(d✘βe)“個(gè)體(tǐ)化(huà)醫(yī)學”轉變。個(gè₽♠✔γ)體(tǐ)化(huà)醫(yī)學是(shì)根據個(gè)體(tǐφ™≤)的(de)基因信息對(duì)疾病 進行(xíng)診斷、治療×÷和(hé)風(fēng)險評估，使疾病的(de)σβ診治更為(wèi)精确、高(gāo)效，顯著提升醫→ε÷(yī)療質量。個(gè)體(tǐ)化(huà)醫(yī™©‍ )學目前發 展最為(wèi)成♦ 熟的(de)領域是(shì)個(gè)體(tǐ)化(hγπuà)用(yòng)藥，即以每個(gè)患者的(de∞π•₩)基因信息為(wèi)基礎決定個(gè)人(rén)的(de)藥δ​物(wù)治療方案，從(cóng)基因 組成或表達的(d​₹e)差異來(lái)預測疾病的(de)治療效果或毒副作(™'<zuò)用(yòng)，對(duì)每個(gè)患者選擇最适宜的(de)藥物(♠←↕wù)療法進行(xíng)治療。 ♦ ♦ 個(gè)體(tǐ)化(huà)醫(yī)學彌補了(le)循證醫(yī$≠)學的(de)缺點，其治療更有(yǒu)針對(duì)性，可★βε(kě)以按照(zhào)個(gè)體(tǐ)對(duìσ® )某種特定疾病易感性的(de)不(bù)同 或對(duì)某>☆種特定治療反應性的(de)不(bù)同，把人(rén)群分(fēn)為£®$™(wèi)不(bù)同的(de)亞群，進而對(duì)患者進行(xín₩ g)有(yǒu)效地(dì)預防或治療性幹預， 節約醫(yī≤₽±‌)療費(fèi)用(yòng)和(hé)避免毒副反應Personalize≠γd medicine is an inevitable trend i≥★¥→n the development of medicine in ₽δthe 21st century.With the completi"β on of the human genome projδγ ect and in-depth research on post-©αgenomics, more and more disease-caus☆♣ing genes have been located$↓σ$, and the genetic basis€÷δ↕ of more diseases has been elΩ↑÷ucidated, which is related toπ ' human physiology, pathology, dru÷‍g effects and toxic λφ"side effects. Gene characαγ←×teristics are constanδ∞¥tly being revealed, ♦"prompting the medical model to cha£÷nge from the classic "st×™εandardized medicine" based   on rule summaries to "tailor-↓'made" "individualized medicin≠♦εe" based on individual genetic differe £nces.Personalized medicine is the diag φ>≈nosis, treatment and r∞♥§isk assessment of diseasesαφ∏ based on individual genetic informati× ✘on, making the diagn★‍≥osis and treatment of diseases more"♣™ accurate and efficien✔×t, and significantly improving ♠‍↓'the quality of medical care.The mos‌≤δ✘t mature field of personalized med₩Ω≤icine is personalized medicine, whic≠✔₽€h determines individual drug trδ←¥eatment plans based on each pat>'γ ient'。

個(gè)體(tǐ)化(huà)醫(yī)學檢測Personalized Medicine

通(tōng)過利用(yòng)專業¶©"•(yè)檢測儀器(qì)平台和(hé)配套的(de)試↑>Ω劑、耗材，檢測與疾病的(de)發生(shēng)和(hé)用(yò→‍ng)藥相(xiàng)關基因的(de)結構改變、表∏§∞達 和(hé)代謝(xiè)變化(huà★≠×₹)等，進一(yī)步使用(yòng)數(shù)據庫、分(↕¶×fēn)析模型、軟件(jiàn)等工(gōng)具對(✔₹>πduì)檢測結果進行(xíng)專業(yè)分(fēn ♠<✔)析并對(duì)分(fēn)析結果進行(xíng)專業(yè) ↕≈ δ 咨詢（針對(duì)受檢者及其醫(yī)生(shēng)）↔™§，對(duì)疾病進行(xíng)個(gè)性化(huà)的(✘↔↓de)預測、診斷、治療決策和(hé)檢測的(de)臨床檢測服務。 ☆φ÷←